{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:52Z","timestamp":1794047392159,"version":"4.8.0"},"reference-count":91,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"2","license":[{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic phase chronic myeloid leukemia (CML), while tyrosine kinase inhibitor therapy is the standard treatment, current clinical scoring systems cannot accurately predict the heterogeneous treatment outcomes observed in patients. Biomarkers capable of segregating patients according to outcome at diagnosis are needed to improve management, and facilitate enrollment in clinical trials seeking to prevent blast crisis transformation and improve the depth of molecular responses. To this end, gene expression (GE) profiling studies have evaluated whether GE signatures at diagnosis are clinically informative. Patient material from a variety of sources has been profiled using microarrays, RNA sequencing and, more recently, single-cell RNA sequencing. However, differences in the cell types profiled, the technologies used, and the inherent complexities associated with the interpretation of genomic data pose challenges in distilling GE datasets into biomarkers with clinical utility. The goal of this paper is to review previous studies evaluating GE profiling in CML, and explore their potential as risk assessment tools for individualized CML treatment. We also review the contribution that acquired mutations, including those seen in clonal hematopoiesis, make to GE profiles, and how a model integrating contributions of genetic and epigenetic factors in resistance to tyrosine kinase inhibitors and blast crisis transformation can define a route to GE-based biomarkers. Finally, we outline a four-stage approach for the development of GE-based biomarkers in CML.<\/jats:p>","DOI":"10.3324\/haematol.2021.279317","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T03:43:53Z","timestamp":1633578233000},"page":"358-370","source":"Crossref","is-referenced-by-count":25,"title":["Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers"],"prefix":"10.3324","volume":"107","author":[{"given":"Vaidehi","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Tiong","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2021,10,7]]},"reference":[{"key":"33283","doi-asserted-by":"crossref","unstructured":"Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243(5405):290-293.","DOI":"10.1038\/243290a0"},{"key":"33284","doi-asserted-by":"crossref","unstructured":"Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010; 120(7):2254-2264.","DOI":"10.1172\/JCI41246"},{"key":"33285","doi-asserted-by":"crossref","unstructured":"Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13):4808-4817.","DOI":"10.1182\/blood-2008-07-077958"},{"key":"33286","doi-asserted-by":"crossref","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017; 129(12):1595-1606.","DOI":"10.1182\/blood-2016-09-696013"},{"key":"33287","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"33288","doi-asserted-by":"crossref","unstructured":"Mahon FX, Rea D, Guilhot J. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11):1029-1035.","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"33289","doi-asserted-by":"crossref","unstructured":"Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020; 17(8):493-503.","DOI":"10.1038\/s41571-020-0367-1"},{"key":"33290","doi-asserted-by":"crossref","unstructured":"Branford S, Fletcher L, Cross NC. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112(8):3330-3338.","DOI":"10.1182\/blood-2008-04-150680"},{"key":"33291","doi-asserted-by":"crossref","unstructured":"Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):433-442.","DOI":"10.1182\/hematology.2019000050"},{"key":"33292","doi-asserted-by":"crossref","unstructured":"Ko TK, Javed A, Lee KL. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood. 2020; 135(26):2337-2353.","DOI":"10.1182\/blood.2020004834"},{"key":"33293","doi-asserted-by":"crossref","unstructured":"McWeeney SK, Pemberton LC, Loriaux MM. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood. 2010; 115(2):315-325.","DOI":"10.1182\/blood-2009-03-210732"},{"key":"33294","doi-asserted-by":"crossref","unstructured":"Mohty M, Yong AS, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood. 2007; 110(1):380-383.","DOI":"10.1182\/blood-2006-12-065599"},{"key":"33295","doi-asserted-by":"crossref","unstructured":"Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood. 2006; 107(1):205-212.","DOI":"10.1182\/blood-2005-05-2155"},{"key":"33296","doi-asserted-by":"crossref","unstructured":"Branford S, Wang P, Yeung DT. Integrative genomic analysis reveals cancerassociated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018; 132(9):948-961.","DOI":"10.1182\/blood-2018-02-832253"},{"key":"33297","doi-asserted-by":"crossref","unstructured":"Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020; 12(1):8.","DOI":"10.1186\/s13073-019-0703-1"},{"key":"33298","doi-asserted-by":"crossref","unstructured":"Kaneta Y, Kagami Y, Katagiri T. Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res. 2002; 93(8):849-856.","DOI":"10.1111\/j.1349-7006.2002.tb01328.x"},{"key":"33299","doi-asserted-by":"crossref","unstructured":"McLean LA, Gathmann I, Capdeville R, Polymeropoulos MH, Dressman M. Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res. 2004; 10(1 Pt 1):155-165.","DOI":"10.1158\/1078-0432.CCR-0784-3"},{"key":"33300","doi-asserted-by":"crossref","unstructured":"de Lavallade H, Finetti P, Carbuccia N. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res. 2010; 34(2):254-257.","DOI":"10.1016\/j.leukres.2009.09.026"},{"key":"33301","doi-asserted-by":"crossref","unstructured":"Zhang WW, Cortes JE, Yao H. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009; 27(22):3642-3649.","DOI":"10.1200\/JCO.2008.19.4076"},{"key":"33302","doi-asserted-by":"crossref","unstructured":"Kok CH, Yeung DT, Lu L. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 2019; 3(10):1610-1621.","DOI":"10.1182\/bloodadvances.2019000195"},{"key":"33303","doi-asserted-by":"crossref","unstructured":"Marin D, Ibrahim AR, Lucas C. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012; 30(3):232-238.","DOI":"10.1016\/j.yonc.2012.07.031"},{"key":"33304","doi-asserted-by":"crossref","unstructured":"Hughes TP, Saglio G, Kantarjian HM. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014; 123(9):1353-1360.","DOI":"10.1182\/blood-2013-06-510396"},{"key":"33305","doi-asserted-by":"crossref","unstructured":"Frank O, Brors B, Fabarius A. Gene expression signature of primary imatinibresistant chronic myeloid leukemia patients. Leukemia. 2006; 20(8):1400-1407.","DOI":"10.1038\/sj.leu.2404270"},{"key":"33306","doi-asserted-by":"crossref","unstructured":"Villuendas R, Steegmann JL, Pollan M. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia. 2006; 20(6):1047-1054.","DOI":"10.1038\/sj.leu.2404197"},{"key":"33307","doi-asserted-by":"crossref","unstructured":"Radich JP, Dai H, Mao M. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006; 103(8):2794-2799.","DOI":"10.1073\/pnas.0510423103"},{"key":"33308","doi-asserted-by":"crossref","unstructured":"Lim S, Saw TY, Zhang M. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function. Proc Natl Acad Sci U S A. 2013; 110(25):E2298-2307.","DOI":"10.1073\/pnas.1301838110"},{"key":"33309","unstructured":"Crossman LC, Mori M, Hsieh YC. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica. 2005; 90(4):459-464."},{"key":"33310","doi-asserted-by":"crossref","unstructured":"Burguillo FJ, Martin J, Barrera I, Bardsley WG. Meta-analysis of microarray data: the case of imatinib resistance in chronic myelogenous leukemia. Comput Biol Chem. 2010; 34(3):184-192.","DOI":"10.1016\/j.compbiolchem.2010.06.003"},{"key":"33311","doi-asserted-by":"crossref","unstructured":"Jamieson CH, Ailles LE, Dylla SJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004; 351(7):657-667.","DOI":"10.1056\/NEJMoa040258"},{"key":"33312","doi-asserted-by":"crossref","unstructured":"Lim B, Lin Y, Navin N. Advancing cancer research and medicine with single-cell genomics. Cancer Cell. 2020; 37(4):456-470.","DOI":"10.1016\/j.ccell.2020.03.008"},{"key":"33313","doi-asserted-by":"crossref","unstructured":"Warfvinge R, Geironson L, Sommarin MNE. Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML. Blood. 2017; 129(17):2384-2394.","DOI":"10.1182\/blood-2016-07-728873"},{"key":"33314","doi-asserted-by":"crossref","unstructured":"Giustacchini A, Thongjuea S, Barkas N. Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nat Med. 2017; 23(6):692-702.","DOI":"10.1038\/nm.4336"},{"key":"33315","doi-asserted-by":"crossref","unstructured":"Inselmann S, Wang Y, Saussele S. Development, function, and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia. Cancer Res. 2018; 78(21):6223-6234.","DOI":"10.1158\/0008-5472.CAN-18-1477"},{"key":"33316","doi-asserted-by":"crossref","unstructured":"Sinnakannu JR, Lee KL, Cheng S. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. Leukemia. 2020; 34(7):1787-1798.","DOI":"10.1038\/s41375-020-0732-1"},{"key":"33317","doi-asserted-by":"crossref","unstructured":"Oehler VG, Yeung KY, Choi YE. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood. 2009; 114(15):3292-3298.","DOI":"10.1182\/blood-2009-03-212969"},{"key":"33318","doi-asserted-by":"crossref","unstructured":"Zheng C, Li L, Haak M. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia. 2006; 20(6):1028-1034.","DOI":"10.1038\/sj.leu.2404227"},{"key":"33319","doi-asserted-by":"crossref","unstructured":"Branford S, Kim DDH, Apperley JF. Laying the foundation for genomicallybased risk assessment in chronic myeloid leukemia. Leukemia. 2019; 33(8):1835-1850.","DOI":"10.1038\/s41375-019-0512-y"},{"key":"33320","doi-asserted-by":"crossref","unstructured":"Zhao LJ, Wang YY, Li G. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine fullblown leukemia. Blood. 2012; 119(12):2873-2882.","DOI":"10.1182\/blood-2011-08-370981"},{"key":"33321","doi-asserted-by":"crossref","unstructured":"Joshi I, Yoshida T, Jena N. Loss of Ikaros DNA-binding function confers integrin- dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol. 2014; 15(3):294-304.","DOI":"10.1038\/ni.2821"},{"key":"33322","doi-asserted-by":"crossref","unstructured":"Balasubramani A, Larjo A, Bassein JA. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex. Nat Commun. 2015; 6:7307.","DOI":"10.1038\/ncomms8307"},{"key":"33323","doi-asserted-by":"crossref","unstructured":"Pagan JK, Arnold J, Hanchard KJ. A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP. J Biol Chem. 2007; 282(20):15248-15257.","DOI":"10.1074\/jbc.M700246200"},{"key":"33324","doi-asserted-by":"crossref","unstructured":"Kazenwadel J, Secker GA, Liu YJ. Loss-of-function germline GATA2 mutations in patients with MDS\/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood. 2012; 119(5):1283-1291.","DOI":"10.1182\/blood-2011-08-374363"},{"key":"33325","doi-asserted-by":"crossref","unstructured":"Zhang SJ, Shi JY, Li JY. GATA-2 L359V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism. Leuk Res. 2009; 33(8):1141-1143.","DOI":"10.1016\/j.leukres.2009.02.025"},{"key":"33326","doi-asserted-by":"crossref","unstructured":"Pronier E, Almire C, Mokrani H. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011; 118(9):2551-2555.","DOI":"10.1182\/blood-2010-12-324707"},{"key":"33327","doi-asserted-by":"crossref","unstructured":"Moran-Crusio K, Reavie L, Shih A. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011; 20(1):11-24.","DOI":"10.1016\/j.ccr.2011.06.001"},{"key":"33328","doi-asserted-by":"crossref","unstructured":"Mayle A, Yang L, Rodriguez B. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood. 2015; 125(4):629-638.","DOI":"10.1182\/blood-2014-08-594648"},{"key":"33329","doi-asserted-by":"crossref","unstructured":"Hervouet E, Peixoto P, Delage-Mourroux R, Boyer-Guittaut M, Cartron PF. Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clin Epigenetics. 2018; 10:17.","DOI":"10.1186\/s13148-018-0450-y"},{"key":"33330","doi-asserted-by":"crossref","unstructured":"Huang Y-H, Tovy A, Sundaramurthy V. Nearly a third of clonal hematopoiesisassociated DNMT3A mutations reduce protein stability and may be associated with poorer prognosis. Blood. 2018; 132(Suppl 1):1315.","DOI":"10.1182\/blood-2018-99-115275"},{"key":"33331","doi-asserted-by":"crossref","unstructured":"Adnan Awad S, Dufva O, Ianevski A. RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia. 2021; 35(4):1087-1099.","DOI":"10.1038\/s41375-020-01011-5"},{"key":"33332","doi-asserted-by":"crossref","unstructured":"Warsch W, Kollmann K, Eckelhart E. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood. 2011; 117(12):3409-3420.","DOI":"10.1182\/blood-2009-10-248211"},{"key":"33333","doi-asserted-by":"crossref","unstructured":"Beer PA, Knapp DJ, Miller PH. Disruption of IKAROS activity in primitive chronic-phase CML cells mimics myeloid disease progression. Blood. 2015; 125(3):504-515.","DOI":"10.1182\/blood-2014-06-581173"},{"key":"33334","doi-asserted-by":"crossref","unstructured":"Thomson DW, Shahrin NH, Wang PPS. Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2020; 34(8):2051-2063.","DOI":"10.1038\/s41375-020-0751-y"},{"key":"33335","doi-asserted-by":"crossref","unstructured":"Giotopoulos G, van der Weyden L, Osaki H. A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression. J Exp Med. 2015; 212(10):1551-1569.","DOI":"10.1084\/jem.20141661"},{"key":"33336","doi-asserted-by":"crossref","unstructured":"Yang H, Kurtenbach S, Guo Y. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies. Blood. 2018; 131(3):328-341.","DOI":"10.1182\/blood-2017-06-789669"},{"key":"33337","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019; 366(6465):eaan4673.","DOI":"10.1126\/science.aan4673"},{"key":"33338","doi-asserted-by":"crossref","unstructured":"Schmidt M, Rinke J, Schafer V. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014; 28(12):2292-2299.","DOI":"10.1038\/leu.2014.272"},{"key":"33339","doi-asserted-by":"crossref","unstructured":"Kim T, Tyndel MS, Kim HJ. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017; 129(1):38-47.","DOI":"10.1182\/blood-2016-04-708560"},{"key":"33340","doi-asserted-by":"crossref","unstructured":"Jeong M, Sun D, Luo M. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat Genet. 2014; 46(1):17-23.","DOI":"10.1038\/ng.2836"},{"key":"33341","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab O, Gao J, Adli M. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013; 210(12):2641-2659.","DOI":"10.1084\/jem.20131141"},{"key":"33342","doi-asserted-by":"crossref","unstructured":"Sano S, Oshima K, Wang Y. CRISPRmediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ Res. 2018; 123(3):335-341.","DOI":"10.1161\/CIRCRESAHA.118.313225"},{"key":"33343","doi-asserted-by":"crossref","unstructured":"Sano S, Oshima K, Wang Y. Tet2- mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta\/NLRP3 inflammasome. J Am Coll Cardiol. 2018; 71(8):875-886.","DOI":"10.1016\/j.jacc.2017.12.037"},{"key":"33344","doi-asserted-by":"crossref","unstructured":"Arends CM, Galan-Sousa J, Hoyer K. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018; 32(9):1908-1919.","DOI":"10.1038\/s41375-018-0047-7"},{"key":"33345","doi-asserted-by":"crossref","unstructured":"Welner RS, Amabile G, Bararia D. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell. 2015; 27(5):671-681.","DOI":"10.1016\/j.ccell.2015.04.004"},{"key":"33346","doi-asserted-by":"crossref","unstructured":"Hughes A, Yong ASM. Immune effector recovery in chronic myeloid leukemia and treatment-free remission. Front Immunol. 2017; 8:469.","DOI":"10.3389\/fimmu.2017.00469"},{"key":"33347","doi-asserted-by":"crossref","unstructured":"Hughes A, Clarson J, Tang C. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors. Blood. 2017; 129(9):1166-1176.","DOI":"10.1182\/blood-2016-10-745992"},{"key":"33348","doi-asserted-by":"crossref","unstructured":"Yong AS, Keyvanfar K, Hensel N. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood. 2009; 113(4):875-882.","DOI":"10.1182\/blood-2008-05-158253"},{"key":"33349","doi-asserted-by":"crossref","unstructured":"Koschmieder S, Vetrie D. Epigenetic dysregulation in chronic myeloid leukaemia: a myriad of mechanisms and therapeutic options. Semin Cancer Biol. 2018; 51:180-197.","DOI":"10.1016\/j.semcancer.2017.07.006"},{"key":"33350","doi-asserted-by":"crossref","unstructured":"Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006; 6(11):846-856.","DOI":"10.1038\/nrc1991"},{"key":"33351","doi-asserted-by":"crossref","unstructured":"Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer. 2013; 109(2):299-306.","DOI":"10.1038\/bjc.2013.281"},{"key":"33352","doi-asserted-by":"crossref","unstructured":"Wong SJ, Gearhart MD, Taylor AB. KDM2B recruitment of the polycomb group complex, PRC1.1, requires cooperation between PCGF1 and BCORL1. Structure. 2016; 24(10):1795-1801.","DOI":"10.1016\/j.str.2016.07.011"},{"key":"33353","doi-asserted-by":"crossref","unstructured":"Yu M, Mazor T, Huang H. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012; 45(3):330-343.","DOI":"10.1016\/j.molcel.2011.11.032"},{"key":"33354","doi-asserted-by":"crossref","unstructured":"Oravecz A, Apostolov A, Polak K. Ikaros mediates gene silencing in T cells through Polycomb repressive complex 2. Nat Commun. 2015; 6:8823.","DOI":"10.1038\/ncomms9823"},{"key":"33355","doi-asserted-by":"crossref","unstructured":"Xie H, Peng C, Huang J. Chronic myelogenous leukemia-initiating cells require polycomb group protein EZH2. Cancer Discov. 2016; 6(11):1237-1247.","DOI":"10.1158\/2159-8290.CD-15-1439"},{"key":"33356","doi-asserted-by":"crossref","unstructured":"Scott MT, Korfi K, Saffrey P. Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition. Cancer Discov. 2016; 6(11):1248-1257.","DOI":"10.1158\/2159-8290.CD-16-0263"},{"key":"33357","doi-asserted-by":"crossref","unstructured":"Rizo A, Horton SJ, Olthof S. BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood. 2010; 116(22):4621-4630.","DOI":"10.1182\/blood-2010-02-270660"},{"key":"33358","doi-asserted-by":"crossref","unstructured":"Sengupta A, Ficker AM, Dunn SK, Madhu M, Cancelas JA. Bmi1 reprograms CML Blymphoid progenitors to become B-ALLinitiating cells. Blood. 2012; 119(2):494-502.","DOI":"10.1182\/blood-2011-06-359232"},{"key":"33359","doi-asserted-by":"crossref","unstructured":"Behzad MM, Shahrabi S, Jaseb K. Aberrant DNA methylation in chronic myeloid leukemia: cell fate control, prognosis, and therapeutic response. Biochem Genet. 2018; 56(3):149-175.","DOI":"10.1007\/s10528-018-9841-1"},{"key":"33360","doi-asserted-by":"crossref","unstructured":"Heller G, Topakian T, Altenberger C. Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia. Leukemia. 2016; 30(9):1861-1868.","DOI":"10.1038\/leu.2016.143"},{"key":"33361","doi-asserted-by":"crossref","unstructured":"Mancini M, Veljkovic N, Leo E. Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia. J Cell Biochem. 2012; 113(8):2765-2774.","DOI":"10.1002\/jcb.24154"},{"key":"33362","doi-asserted-by":"crossref","unstructured":"Amabile G, Di Ruscio A, Muller F. Dissecting the role of aberrant DNA methylation in human leukaemia. Nat Commun. 2015; 6:7091.","DOI":"10.1038\/ncomms8091"},{"key":"33363","doi-asserted-by":"crossref","unstructured":"Issa JP, Gharibyan V, Cortes J. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005; 23(17):3948-3956.","DOI":"10.1200\/JCO.2005.11.981"},{"key":"33364","doi-asserted-by":"crossref","unstructured":"Visvader JE. Cells of origin in cancer. Nature. 2011; 469(7330):314-322.","DOI":"10.1038\/nature09781"},{"key":"33365","doi-asserted-by":"crossref","unstructured":"Huntly BJ, Shigematsu H, Deguchi K. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004; 6(6):587-596.","DOI":"10.1016\/j.ccr.2004.10.015"},{"key":"33366","doi-asserted-by":"crossref","unstructured":"Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood. 1998; 92(9):3362-3367.","DOI":"10.1182\/blood.V92.9.3362"},{"key":"33367","doi-asserted-by":"crossref","unstructured":"Sparano JA, Gray RJ, Makower DF. Adjuvant chemotherapy guided by a 21- gene expression assay in breast cancer. N Engl J Med. 2018; 379(2):111-121.","DOI":"10.1056\/NEJMoa1804710"},{"key":"33368","doi-asserted-by":"crossref","unstructured":"Ng SW, Mitchell A, Kennedy JA. A 17- gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016; 540(7633):433-437.","DOI":"10.1038\/nature20598"},{"key":"33369","doi-asserted-by":"crossref","unstructured":"Bill M, Nicolet D, Kohlschmidt J. Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia. Haematologica. 2020; 105(3):721-729.","DOI":"10.3324\/haematol.2019.225003"},{"key":"33370","doi-asserted-by":"crossref","unstructured":"Shanmuganathan N, Pagani IS, Ross DM. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatmentfree remission in chronic myeloid leukemia. Blood. 2021; 137(9):1196-1207.","DOI":"10.1182\/blood.2020005514"},{"key":"33371","doi-asserted-by":"crossref","unstructured":"Radich JP, Larson R, Kantarjian H. Gene expression signature predicts deep molecular response (DMR) in chronic myeloid leukemia (CML): an exploratory biomarker analysis from ENESTnd [Abstract]. Blood. 2019; 34(Suppl_1):665.","DOI":"10.1182\/blood-2019-124716"},{"key":"33372","doi-asserted-by":"crossref","unstructured":"Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017; 14(10):595-610.","DOI":"10.1038\/nrclinonc.2017.74"},{"key":"33373","doi-asserted-by":"crossref","unstructured":"Teutsch SM, Bradley LA, Palomaki GE. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009; 11(1):3-14.","DOI":"10.1097\/GIM.0b013e318184137c"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279317\/73754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2021.279317\/74072","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10418\/73754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:00:29Z","timestamp":1794045629000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2021.279317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,7]]},"references-count":91,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2021.279317","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10,7]]}}}